[1] Cerný E, Bucek J. Tumor-related partial pseudocirrhosis of the liver[J]. Cesk Patol, 1992, 28(1):53-56.
[2] Young ST, Paulson EK, Washington K, et al. CT of the liver in patients with metastatic breast carcinoma treated by chemotherapy: findings simulating cirrhosis[J]. AJR Am J Roentgenol, 1994, 163(6):1385-1388.
[3] Harry BL, Smith ML, Burton JR Jr, et al. Medullary thyroid cancer and pseudocirrhosis: case report and literature review[J]. Curr Oncol, 2012, 19(1):e36-e41.
[4] 赵馨悦,魏来. 假性肝硬化的研究进展[J]. 中华肝脏病杂志, 2024, 32(3):273-278.
[5] Vuppalanchi R, Saxena R, Storniolo AMV, et al. Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib[J]. Hepatology, 2017, 65(5):1762-1764.
[6] Oliai C, Douek ML, Rhoane C, et al. Clinical features of pseudocirrhosis in metastatic breast cancer[J]. Breast Cancer Res Treat, 2019, 177(2):409-417.
[7] Engelman D, Moreau M, Lepida A, et al. Metastatic breast cancer and pseudocirrhosis: an unknown clinical entity[J]. ESMO Open, 2020, 5(3):e000695.
[8] Huppert LA, Walker Z, Li M, et al. Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study[J]. Breast Cancer Res Treat, 2023,197(1):137-148.
[9] Phillips E, Sethi M, Vasanthakumar S, et al. The Clinical Features and Outcomes of Pseudocirrhosis in Breast Cancer.[J] Cancers (Basel), 2024,16(16):2822.
[10] Kang SP, Taddei T, McLennan B, et al. Pseudocirrhosis in a pancreatic cancer patient with liver metastases: a case report of complete resolution of pseudocirrhosis with an early recognition and management[J]. World J Gastroenterol, 2008,14(10):1622-1624.
[11] Kobashigawa C, Nakamoto M, Hokama A, et al. Pseudocirrhosis in metastatic esophageal cancer[J]. South Med J, 2010,103(5):488-489.
[12] Battisti S, Guida FM, Pagliara E, et al. Pseudocirrhosis after anti-EGFR-based neoadjuvant therapy for hepatic metastasis from colon cancer: a different point of view[J]. Clin Colorectal Cancer, 2014,13(3):e13-e15.
[13] Mitani S, Kadowaki S, Taniguchi H, et al. Pseudocirrhosis in Gastric Cancer with Diffuse Liver Metastases after a Dramatic Response to Chemotherapy[J]. Case Rep Oncol,2016,9(1):106-111.
[14] Nakano S, Suzuki T, Takase Y, et al. Pseudocirrhosis caused by lung adenocarcinoma with diffuse liver metastasis: An autopsy case report[J]. Thorac Cancer,2021,12(13):2046-2049.
[15] Shijubou N, Sumi T, Keira Y, et al. Pseudocirrhosis due to liver metastasis from lung adenocarcinoma[J]. Thorac Cancer,2021,12(17):2407-2410.
[16] Mir AS, Lebel DP, Grider DJ. Pseudo-cirrhosis secondary to sinusoidal obstruction from metastatic breast carcinoma[J]. Indian J Gastroenterol. Published online August 16, 2023.
[17] Sonnenblick A, Appelbaum L, Peretz T. Liver failure on the background of pseudocirrhosis in patients with liver metastasis from breast cancer, who responded to treatment[J]. Onkologie,2011,34(4):199-201.
[18] Kumamoto K, Endo S, Isohata N, et al. Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases[J]. Mol Clin Oncol,2017,6(1):63-66.
[19] Zanazanian A, Kalani A, Tabibian JH. Pseudocirrhosis in a Patient with New-Onset Dysphagia and History of Ovarian Carcinoma[J]. ACG Case Rep J, 2018,5:e29.
[20] Torri GB, Soldatelli MD, Luersen GF, et al. Imaging of chemotherapy-induced liver toxicity: an illustrated overview[J]. Hepat Oncol, 2021,8(4):HEP32.
[21] Gopalakrishnan D, Shajihan A, Purysko AS, et al. Pseudocirrhosis in Breast Cancer - Experience From an Academic Cancer Center[J]. Front Oncol, 2021, 11:679163.
[22] Leshchinskiy S, Kanner C, Keating DP. Pseudocirrhosis[J]. Abdom Radiol (NY), 2018,43(11):3197-3198.
[23] Shreve LA, O'Leary C, Clark TWI, et al. Transjugular intrahepatic portosystemic shunt for the management of symptomatic malignant pseudocirrhosis[J]. J Gastrointest Oncol, 2022, 13(1):279-287.
[24] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension[J]. J Hepatol,2022,77(1):271.
[25] Zhu C, Ren X, Liu D, et al. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome[J]. Toxicology, 2021,460:152882.
[26] Kaplan DE, Ripoll C, Thiele M, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis[J]. Hepatology,2024,79(5):1180-1211.
[27] Geeroms B, De Hertogh G, Vanslembrouck R, et al. Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Portal Hypertension-Induced Refractory Ascites Due to Metastatic Carcinomatous Liver Disease[J]. J Vasc Interv Radiol, 2018, 29(12):1713-1716.
[28] Mizukami S, Shonaka T, Tani C, et al. A case of percutaneous transhepatic stomal varices embolization and partial splenic artery embolization for rectal cancer after CAPOX/BEV chemotherapy: the summary of the stomal varices related to oxaliplatin administration[J]. Clin J Gastroenterol,2023,16(1):54-62.
[29] Bonney GK, Chew CA, Lodge P, et al. Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines[J]. Lancet Gastroenterol Hepatol,2021,6(11):933-946.
[30] Villani R, Di Cosimo F, Sangineto M, et al. Pseudocirrhosis and portal hypertension in patients with metastatic cancers: a systematic review and meta-analysis[J]. Sci Rep, 2022,12(1):19865. |
